TransMedics Gr Analyst Ratings
Stephens & Co. Maintains Overweight on TransMedics Gr, Raises Price Target to $178
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $153 to $200
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Sticks to Their Hold Rating for Hims & Hers Health (HIMS)
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $137
Lantheus Holdings: A Strong Buy on Robust Q2 Performance and Strategic Growth Investments
Axos Financial Analyst Ratings
Lantheus Holdings Price Target Cut to $135.00/Share From $141.00 by Truist Securities
Lantheus Holdings Analyst Ratings
TransMedics Gr Analyst Ratings
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $200
Truist Financial Keeps Their Buy Rating on Lantheus (LNTH)
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
JMP Securities Maintains Lantheus(LNTH.US) With Buy Rating, Cuts Target Price to $125
Lantheus Holdings: A Strong Buy on Robust Revenue Growth and Promising Pipeline
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $145
Strong Performance and Growth Prospects Justify Buy Rating for Lantheus